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Abstract
Background: Influenza is a severe contagious disease especially in children, elderly and immunocompromised
patients. Beside vaccination, the discovery of new anti-viral agents represents an important strategy to encounter
seasonal and pandemic influenza A virus (IAV) strains. The bacterial extra-cellular ribonuclease binase is a well-studied
RNase from Bacillus pumilus. Treatment with binase was shown to improve survival of laboratory animals infected with
different RNA viruses. Although binase reduced IAV titer in vitro and in vivo, the mode of action (MOA) of binase
against IAV at the molecular level has yet not been studied in depth and remains elusive.
Methods: To analyze whether binase impairs virus replication by direct interaction with the viral particle we applied a
hemagglutination inhibition assay and monitored the integrity of the viral RNA within the virus particle by RT-PCR.
Furthermore, we used Western blot and confocal microscopy analysis to study whether binase can internalize into
MDCK-II cells. By primer extension we examined the effect of binase on the integrity of viral RNAs within the cells and
using a mini-genome system we explored the effect of binase on the viral expression.
Results: We show that (i) binase does not to attack IAV particle-protected viral RNA, (ii) internalized binase could be
detected within the cytosol of MDCK-II cells and that (iii) binase impairs IAV replication by specifically degrading viral
RNA species within the infected MDCK-II cells without obvious effect on cellular mRNAs.
Conclusion: Our data provide novel evidence suggesting that binase is a potential anti-viral agent with specific
intra-cellular MOA.
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Background
Influenza A virus (IAV) is an RNA virus, which poses a
great health risk causing seasonal epidemics and periodic-
ally worldwide pandemics. Despite their seasonal charac-
ter, influenza epidemics are unpredictable and have been
recognized as a major cause of morbidity and increased
mortality [1]. Influenza virus infection leads to a disease
that results in 0.25–0.5 million deaths annually worldwide
[2]. Currently, two classes of anti-virals are available for
the treatment of seasonal human influenza: neuraminidase
inhibitors (oseltamivir, zanamivir, peramivir) and M2-
channel blockers (rimantadine and amantadine) acting on
viral spread and entry, respectively [3]. Nevertheless, vac-
cination is still the most effective preventive measure, re-
gardless to the constant changes of the viral antigenic
epitopes (antigen drift), demanding the annual renewal of
the selected vaccine strains [4, 5]. Furthermore, based on
the segmented nature of IAV genome, co-infections can
lead to reassortants with completely new antigenic charac-
teristics (antigen shift) that can cause pandemic outbreaks
[6, 7]. Thus, the efficacy of currently approved control
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strategies is limited because IAVs frequently escape the
immune response via antigen drift and shift [8]. Therefore,
an alternative therapeutic strategy that is effective irre-
spective of viral subtype by directly attacking the genetic
material of the virus would be beneficial.
Along this line, ribonucleases (RNases) might represent
an attractive tool [9, 10]. It was previously shown that
certain amphibian RNases possess anti-viral activities
[11, 12]. Onconase from Rana pipiens selectively destroyed
the RNA of type-I human immunodeficiency virus (HIV-I)
without degrading host RNA molecules [11] and RNase
from Rana catesbeiana inhibited the replication of Japanese
encephalitis virus [12]. Recently, we have shown that binase,
an extra-cellular RNase of the gram-positive bacteria
Bacillus pumilus, reduced the titer of an 2009 pandemic
IAV strain (H1N1pdm09) in A549 cells at non-toxic
concentrations [13].
Binase is a well-characterized small (12.2 kDa) RNase
[9, 14]. Owing to its bacterial origin, binase evades mam-
malian RNase inhibitors and retains its catalytic activity
inside eukaryotic organisms [15]. Binase was previously
shown to possess in vitro anti-viral properties against foot-
and-mouth disease virus, IAV, reo- and corona- viruses
[13, 16–18]. In vivo, binase protected laboratory animals
from rabies when it was injected into the site of viral ad-
ministration and was also efficient against IAV and influ-
enza B virus (IBV) in infected mice [19, 20].
Nevertheless, mechanisms underlying the anti-viral ef-
fects of binase remain unclear. We had previously
shown that pre-treatment of IAV with binase before in-
fection of A549 and MDCK-II cells resulted in an anti-
viral effect that was dependent on the amount of binase
[13, 21, 22]. Furthermore, we reported that binase de-
grades vRNA, which is not protected by the virion/RNP
complex and that binase added to cells (HEK293, A549)
reduces of a GFP reporter gene expression by a transient
IAV mini-genome system [21, 22]. Moreover, we showed
that binase is able to penetrate into A549 cells [23] and
that treatment of IAV-infected A549 cells led to titer re-
duction and reduced the viral NP mRNA amount 12 h
post-infection (h p.i.) without affecting mRNA levels of
cellular housekeeping proteins [22].
Since the anti-viral activity of binase against IAV is
evident, it was necessary to investigate whether (i) an
extra-cellular effect of binase on the virion and/or (ii)
the binding of the virion to the cell surface receptors con-
tributes to the virus titer reduction, and was not investi-
gated what type of viral RNAs are affected by binase within
the cell and how this is reflected on the protein level. Also,
it was not previously elucidated whether the anti-viral ac-
tivity of binase coincides with its internalization in other
cells (MDCK-II, optimal for IAV propagation).
Hence, we sought to elucidate in more detail the extra-
and intra-cellular effect of binase on viral gene expression
and protein production in order to establish a more robust
basis of its anti-viral mode of action.
Methods
Cells and viruses
MDCK-II (Madin-Darby canine kidney epithelial cells)
and 293 T (Human embryonic kidney (HEK) constitu-
tively expressing the SV40 large T antigen) (ATCC, USA)
were cultured in Dulbecco’s modified Eagle medium
(DMEM) (Gibco, USA) supplemented with 10% fetal calf
serum (FCS, PAA, Austria), 100 U/ml penicillin and
0.1 mg/ml streptomycin (P/S) (Gibco, USA) and incubated
at 37 °C in a 5% CO2 atmosphere. Influenza virus A/
Hamburg/04/09 (H1N1pdm09) and A/Victoria/3/1975
(H3N2-Vict) were propagated in MDCK-II cells at 37 °C
and 5% CO2. The virus was titrated using focus assay
[24, 25] and stored at −80 °C.
Plasmids and primers
For the in vitro reconstitution of the biological active viral
ribonucleoprotein (vRNP) complex, four plasmids encoding
the viral PB1, PB2, PA and NP proteins of H1N1pdm09
(pHW-PB1-Hamburg, -PB2-Hamburg, -PA-Hamburg,
-NP-Hamburg) together with the plasmid pPol1-CAT-
RT generating a vRNA-like Pol1-transcript encoding
the chloramphenicol acetyltransferase (CAT) protein,
were used. The CAT reporter protein, in negative-sense, is
flanked by the 3′- and 5′-noncoding region of the NS-
segment of influenza A/WSN/33 virus placed between a
truncated human RNA polymerase I promoter (Pol1) and
the hepatitis delta virus ribozyme. The expressed subunits
of the viral polymerases and nucleoprotein replicate and
transcribe the IV-like RNA expressed by pPol1-CAT-RT
into mRNA [26].
RT-qPCR primer pairs (ATPase_F: 5′- TGC TCT CTC
CTT GGA ACC TGT G -3′; ATPase_R: 5′- GCT CTC
CTA CTG ACT GCC TTG TC -3′ and TUB_F: 5′- GGA
CTT CAG GGC TTC CTG GTA TTC-3′; TUB_R: 5′-
CTT CTT GCC GTA GTC AAC CGA GAG -3′) were
used to amplify the cellular housekeeping ATP6V0E1
ATPase (encoding the enzyme V-type proton ATPase
subunit e1) and TUBA4A (encoding the cellular structural
protein named Tubulin alpha-4A) genes, respectively. The
primer pairs were used to identify the binase effect on
MDCK-II cellular mRNA after 12 h incubation of MDCK-
II cells with- and without binase using real-time RT-PCR.
Using a LightCycler 480 (Roche Diagnostics, Switzerland)
system, the samples were subjected to the following
thermal cycling conditions: 95 °C for 10 min; 40 cycles
of 95 °C for 15 s; 60 °C for 30 s; and 30 °C for 30 s.
Isolation of binase
Binase (secreted guanyl-preferring ribonuclease of 109
amino acid residues in the single chain; EC 3.1.27.3) was
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isolated from Bacillus pumilus 7p culture fluid as de-
scribed before [18]. Briefly, bacteria were grown until the
early stationary phase in a phosphate-deficient medium at
37 °C with agitation at 200 rpm in a Multitron shaking in-
cubator (INFORS HT, Switzerland). The cells were pelleted
by centrifugation at 6000 g for 30 min at 4 °C. The super-
natant was diluted 1:5 with sterile deionized water after
acidification by glacial acetic acid to pH 5.0 and applied on
the column packed with DE-32 DEAE cellulose (Whatman,
United Kingdom) equilibrated with 10 mM Na acetate buf-
fer (pH 5.0). The eluate was loaded on phosphocellulose
P11 (Whatman, United Kingdom) equilibrated with 10 mM
Na phosphate buffer (pH 5.0). The phosphocellulose was
washed by 10 mM Na phosphate buffer (pH 5.0) until the
A280 dropped below 0.05. Then, the column was equili-
brated with the 20 mM Na phosphate buffer (pH 7.0). The
protein was eluted using 200 mM Na phosphate buffer
(pH 7.0). Further purification of binase was performed
using UNOS6 column equilibrated with 10 mM Na phos-
phate buffer (pH 7.0) and Biologic DuoFlow chromatog-
raphy system (Bio-Rad, USA). Protein was eluted using a
linear gradient of 0–0.3 M NaCl with the flow rate of
2 mL/min. Protein concentration and RNase activity were
determined in the peak fractions. RNase-containing
fractions were concentrated and desalted using Amicon
Ultra-4 centrifugal filter units (Merck, USA). Homo-
geneity and authenticity of the purified enzyme were
confirmed by PAAG electrophoresis, Western blotting
(ECL) and MALDI TOF/TOF mass spectrometry
(UltrafleXtreme, Bruker Corporation, Germany) [27]. Pro-
tein samples were lyophilized as described before [22].
RNase activity assay
Ribonuclease activity of binase was measured by the hy-
drolysis products of high-molecular weight yeast RNA.
Reaction mixture containing 0.5 mg/ml of RNA in
0.1 M Tris-HCl buffer, pH 8.5 and solution of binase
was incubated at 37 °C for 15 min. The enzymatic reac-
tion was stopped by addition of 6.8% cold perchloric
acid on ice. Non-degraded RNA was pelleted by centri-
fugation at 12000 g for 10 min and the supernatant was
used for the measurement of absorption at 260 nm. One
unit of ribonuclease activity corresponded to the quan-
tity of the enzyme that increased the absorption at
260 nm by 1 optical unit as calculated for 1 ml of reac-
tion mixture and for 1 h of incubation considering the
dilution of the enzyme [13, 18].
Cytotoxicity concentration 50% (CC50)
The cytotoxicity of binase for MDCK-II cells was deter-
mined via MTT assay [28]. Briefly, cells incubated with
binase for 24 h were washed and incubated for 90 min
in 200 μl of MTT-mix (growth DMEM medium con-
taining 175 μg/ml MTT = 1-(4,5-dimethylthiazol-2-yl)-
3,5-diphenylformazan; Sigma) and subsequently fixed
with 3.7% PFA (paraformaldehyde) for 30 min at room
temperature (RT). The cells were dried and the tetrazo-
lium crystals were dissolved by adding 200 μl of isopro-
panol to each well. The plates were shaken for 10 min
and analyzed photometrically at 490 nm excitation in
an ELISA reader EL808 (BioTek, USA). The percentage
of cell viability after binase exposure was calculated as
follows: Percentage viability = 100/(MTT value of un-
treated sample x MTT value of inhibitor treated sam-
ple) using GraphPad Prism 5.01 Software (GraphPad
Software, Inc., USA) by plotting the percent of viable
cells as a function of the binase concentration.
Effective concentration 50% (EC50)
The effective concentration (EC50, the concentration of
compound which reduces the virus titer by 50%) of binase
against H1N1pdm09 was determined in MDCK-II cells.
The cells were grown over night in a 48-well plate (n = 3)
in a humidified incubator at 37 °C and 5% CO2. Cell mono-
layers were then washed and infected with H1N1pdm09
virus suspension in PBS++(PBS containing 1 mM MgCl2,
and 0.9 mM CaCl2)/BA (PBS
++ containing 0.21% bovine al-
bumin and P/S) (MOI = 1) for 1 h at RT. After removing
the virus inoculum, cells were then supplemented with
250 μl DMEM/BA (DMEM containing 0.21% bovine al-
bumin and P/S) in each well containing 1 μg/ml TPCK-
treated Trypsin (Sigma Aldrich, Germany) (+/−) binase
at the indicated concentration and incubated for 24 h,
at 37 °C and 5% CO2. The supernatants containing
H1N1pdm09 virus were subsequently assayed for their
viral titers using focus assay [24, 25].
Hemagglutination inhibition assay (HAI)
Ligand/binase interaction: The HAI assay detects neutral-
izing agents to the viral hemagglutinin (HA) by measuring
the inhibition of virus-mediated agglutination of erythro-
cytes. To determine its neutralizing ability (affinity) to-
wards H1N1pdm09 HA receptor binding residues, binase
(105 U/ml) was twofold serially diluted (1:10–1:1280) in
25 μl of 1xPBS in V-shaped well plates. An equal volume
(25 μl) containing four HA units of H1N1pdm09 was
added and then incubated at RT for 30 min. Then 50 μl of
1% chicken erythrocytes in suspension (PBS) was added to
the wells, mixed by shaking the plates on a mechanical
vibrator and incubated at 4 °C until control showed dot
formation.
Binase/receptor interaction: In an additional approach
to analyze the ability of binase to interfere with HA
binding to its receptor on the surface of the chicken
erythrocytes, these were pre-incubated with binase before
virus was added. Briefly, binase (105 U/ml) was serially
diluted in a 96-well microtiter plate in 25 μl 1xPBS and
then 50 μl of 1% erythrocytes was added and incubated
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together for 30 min. Then, 25 μl of four hemagglutinin
units (HAU) of H1N1pdm09 was then added and incu-
bated at 4 °C for 45 min. 1% erythrocytes plus 1xPBS,
binase (105 U/ml) or H1N1pdm09 (4 HAU) were used
as controls. Agglutination patterns were read after
45 min and the HI titer was defined as the reciprocal of
the last dilution of serum that completely inhibited
hemagglutination.
Immunofluorescence assay
To detect the internalization of binase into MDCK-II
cells, the cells were incubated on a glass cover slips in a
6-well plate with or without binase (105 U/ml) for 4 h.
Cell monolayers were then washed twice with PBS++ and
incubated with 3.7% formaldehyde for 10 min at RT for
fixation and washed. To determine the binase accumu-
lation within the cells, cells were incubated with 0.5%
Triton X-100 for 7 min at RT. After washing with PBS++,
the cells were incubated with PBS++ containing 3% BSA
for 20 min at RT. Following washing, rabbit polyclonal
anti-binase primary antibody (1:50, provided by Dr.
Vershinina, Kazan Federal University, Russia) and sub-
sequently chicken monoclonal anti-rabbit Alexa Fluor
488 (1:1000, life technologies, USA) as secondary anti-
body and was added to the permeabilized cells to detect
binase accumulation on- or in the cells. DAPI (0.1 mg/ml
PBS/3%BA, Roth, Germany), was used for nuclei staining.
The binase localization was detected using a LSM 780
confocal microscopy (Carl Zeiss, Germany). The binase
accumulation on the MDCK-II cellular membrane was
checked from time to time using the above-mentioned
assay without 0.5% Triton X-100 treatment.
Binase treatment
To analyze the intra-cellular effect of binase on IAV
propagation, 105 U/ml of binase (12 h p.i., after single-
cycle virus replication) or different concentration of
binase (24 h p.i., after multi-cycle virus replication) were
added to confluent monolayers of MDCK-II cells in
96-well plates containing DMEM/BA medium. Cells
with and without binase were pre-incubated for 4 h at
37 °C in a 5% CO2 atmosphere and were then further
washed twice with PBS++ and subsequently infected
with H1N1pdm09 (MOI = 1) in PBS++/BA for 60 min
at RT. This procedure should prevent interaction be-
tween binase and virus particles outside the cells and
allowed the internalization of the enzyme into the
cells previous to viral infection. After removal of the
virus suspension from the cell surface, the cells were
further incubated for 8 h in 1 × 105 U/ml binase-
containing DMEM/BA medium, then the medium
was removed. Cell monolayers were then washed
twice with PBS++ and fresh binase-free DMEM/BA
medium containing 1 mg/ml TPCK-treated trypsin
was added. Samples of the culture media were col-
lected at 12 h or 24 h p.i. for virus titration via focus
assay [24, 25].
Degradation analysis of vRNA within viral particles
H1N1pdm09 (200 μl) containing cell culture supernatant
(1 × 106 FFU/ml) was incubated with 105 U/ml binase
(final concentration) for 30 min at 37 °C. As a control,
virus was incubated without binase. The viral RNA was
then extracted and purified using “RNeasy total RNA
isolation kit” (Qiagen, Germany) according to the manu-
facturer’s instructions. Then, vRNA of PB2 was amplified
using “SuperScript III One-Step RT-PCR Platinum Taq
High Fidelity” (Invitrogen, USA). Briefly, 100 ng of ex-
tracted vRNA were mixed with 25 μl “2× Reaction Mix”,
2 μl (0.4 μM) of forward and reverse universal primers
[29]. The total volume was adjusted to 50 μl using
nuclease-free water and then subjected to cDNA synthe-
sis at 55 °C for 40 min, followed by pre-denaturation
(94 °C for 2 min), PCR amplification (20, 25, 30, 35 cycles:
94 °C/15 s for denaturation, 58 °C/30 s for annealing and
68 °C/3 min for extension) and final extension (1 cycle:
68 °C/5 min). The RT-PCR products were detected by 1%
agarose gel electrophoreses and gel documentation.
Protein extraction and western blotting
Viral NP protein was detected via western blot analysis.
Briefly, total cellular proteins from H1N1pdm09-infected
MDCK-II cells (MOI = 3), either binase-treated (1 ×
105 U/ml, 4 h before infection and during 8 h p.i.) or left
untreated, were extracted at 4, 6, 8 h p.i. as described be-
fore [30]. The protein concentration of each sample was
measured using Bradford Assay Kit (Bio-Rad, USA). Cell
lysates were subjected to 4–12% SDS-polyacrylamide
gradient gel electrophoresis (Invitrogen, USA) and sub-
sequent Western blotting. The samples were transferred
onto polyvinylidenefluoride (PVDF) membranes (GE
Healthcare, UK) according to the manufacturer’s in-
structions using XCell II Blot Module (Invitrogen, USA).
The NP protein of H1N1pdm09 was detected using a
rabbit polyclonal anti-influenza A (H1N1) virus NP pro-
tein antibody (1:1000, Thermo Scientific, USA). Beta Actin
was detected as loading control using mouse monoclonal
anti-beta Actin antibody (1:5000, Abcam, UK). As sec-
ondary antibodies for detection goat anti-mouse IRDye
800 CW and goat anti-rabbit IRDye 680 CW (1:15,000,
Abcam, UK) were used and detected with Odyssey im-
aging systems (LI-COR, USA). Protein quantification
was performed using “Quantity one” software (Bio-Rad,
USA). To detect the internalized binase for binase-treated
and nontreated MDCK-II cells, we performed western
blot analysis as described previously.
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Primer extension
In 6-well plates, 3 wells of confluent MDCK-II cell
monolayers were infected with H1N1pdm09 at a MOI of
3 either in the absence or presence of binase (1 × 105 U/
ml). The total RNA was extracted using Trizol reagent
(Invitrogen, USA) at 8 h p.i. and processed as previously
described [25, 31, 32]. The gene-specific DNA primers
used were NP mRNA, cRNA (5′-ACCATTCTCCCAA
CAGATGC-3′) and vRNA (5′-ATGATGGAGAGTGCC
AGACC-3′) specific. The cellular 5S rRNA was detected
using specific primer (5′-TCCCAGGCGGTCTCCCAT
CC-3′) and used as an internal control. Transcription
products were analyzed on 7% polyacrylamide gels con-
taining 7 M urea in Tris-borate-EDTA (TBE) buffer and
signals were detected and calculated using a molecular
imager and the Quantity One software (BioRad), respect-
ively. The increases of vRNA, mRNA and cRNA level
(corrected with respect to 5S rRNA) were expressed rela-
tive to values obtained without binase treatment (arbitrar-
ily 100%).
RNA extraction and cDNA preparation
To characterize the effect binase on cellular mRNA
MDCK-II cells were grown for 12 h in a 6-well plate and
were either binase-treated (105 U/ml in DMEM/BA) or
left untreated (DMEM/BA) in triplicate for another 12 h.
After washing with PBS++, cells were collected in PBS and
immediately counted. 106 cells from each sample were
used for RNA extraction and cDNA preparation. The cells
from each sample were lysed with RLT buffer (Qiagen,
Germany). Total RNA was purified using an RNeasy mini
Kit (Qiagen, Germany) according to manufacturer proto-
col. Total RNAs of each sample was eluted using the same
volume of elution buffer. A concentration of 100 ng of
the eluted RNA from each sample was used for reverse
transcription of ATP6V0E1 and TUBA4A mRNA using
MMLV RT Kit (Evrogen, Russia) and the predefined
antisense primers (Section Plasmids and primers) ac-
cording to manufacturer protocol.
Real-time PCR
To quantify cellular mRNA in MDCK-II cells using
qPCRmix-HS SYBR Kit (Evrogen, Russia), 4 μl of each
cDNA preparation (1–100 ng of the above reaction),
0.4 μM of each (forward and reverse) primers, and 1×
qPCRmix-HS SYBR (Evrogen, Russia) were mixed in a
LightCycler 480 Multiwell Plate 96 (Roche Diagnostics,
Switzerland) on ice in the dark and covered by LightCycler
480 Sealing Foil. Thermal cycling was done under the
conditions as described above (Section Plasmids and
primers). The quantification and data analysis was per-
formed using the LightCycler 480 Service Software (Roche
Diagnostics, Switzerland) and identified the binase action
on cellular mRNA accumulation according to the relative
fold-difference of expression levels.
Chloramphenicol acetyl transferase (CAT) activity assay
using a mini-genome system
To investigate the effect of binase on the gene expression
activity of H1N1pdm09, an IAV mini-replicon system
expressing a CAT reporter gene was employed. The
plasmids (pHW200 for H1N1pdm09) encoding the viral
polymerases (PB2, PB1, PA) and nucleoprotein (NP)
were co-transfected together with pPol1-CAT-RT into
293 T cells (grown in 6 well plates) in a ratio of 1:1:1:2:2 as
previously described with minor modifications [33].
Briefly, the transfection mixture consisting of 180 μl
“Opti-MEM” (Thermo Fisher Scientific, USA) contain-
ing a total of 7 μg of plasmid DNA along with 15 μl
“Trans-IT2020” (Mirus Bio, USA) was incubated for
45 min at RT. Then, the mixture was diluted to 1 ml
using “Opti-MEM” and transferred to an 80–90% con-
fluent 293 T cell monolayer to allow transfection. Then,
the cells were incubated for 8 h at 37 °C. Afterwards, the
transfection mixture was replaced with 2 ml Opti-MEM
containing 0.2% BA and P/S with binase or without binase
(1 × 104 U/ml and 1 × 105 U/ml). At 48 h post transfec-
tion, cell lysates were prepared and tested for CAT activity
(1:1000 dilution) as previously described [26].
Statistical analysis
All experiments were performed in 3–8 biological repeats.
Statistical tests and graphical data presentation were
performed using SigmaPlot 10.0 Software (Systat Soft-
ware, Inc., USA), GraphPad Prism 5 Software (GraphPad
Software, Inc., USA) and MS Excel 2010 (Microsoft Cor-
poration, USA). All data are presented as the mean ±
standard deviation of the mean (SD). The significance be-
tween two groups was determined via “Student t-test”.
Biosafety
All experiments using infectious virus were performed
in accordance with the German regulations applicable to
the propagation of influenza viruses (IVs). All experiments
involving pandemic influenza A (H1N1pdm09) virus were
performed using biosafety level 2 (BSL2) containment la-
boratory approved for such use by the local authorities
(RP, Giessen, Germany).
Results
Binase impairs H1N1pdm09 propagation in MDCK-II at
non-toxic concentrations
To elucidate the MOA of binase as anti-viral candidate
against IAV, we used the MDCK-II cell line. The cyto-
toxic concentration of binase resulting in 50% cell death
(CC50) was found to be higher than the highest tested
binase concentration of 1000 μg/ml (approximately to
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1 × 106 U/ml of enzyme activity) (Fig. 1a). Next, we de-
termined the effective concentration binase that in-
hibits H1N1pdm09 propagation by 50% (EC50) to be
6.7 × 103 U/ml (Fig. 1b). Based on the CC50 and EC50
on MDCK-II cells (Fig. 1) 1 × 105 U/ml were selected to
be used for further experiments.
Binase does not interfere with HA/receptor binding and
does not degrade viral RNA within free virus particles
It was previously reported that pre-incubation of virus
with binase resulted in decreased virus titers after infec-
tion [13, 21, 22], that binase could degrade free viral
RNA [21], and that treatment of IAV-infected A549 cells
led to titer reduction [22]. We therefore addressed
whether binase would indeed directly interfere with the
virus receptor binding activity and/or the viral RNA of
the extra-cellular IAV particles.
The HAI analysis revealed that the binase has a negli-
gible affinity towards IAV receptor binding residues
(ligand/binase interaction) or to the surface receptors
on chicken erythrocytes (binase/receptor interaction)
and therefore did not interfere with viral attachment to
red blood cells. The HAI titers were below the limit of
detection (<1:10) (Additional file 1: Figure S1). Add-
itionally, we found that the anti-viral activity of binase
was not related to a direct interaction with viral RNA
within intact viral particles. Envelope- and viral ribonu-
cleoprotein complex (vRNP)-protected viral RNA gen-
ome of H1N1pdm09 was not affected by binase
following 30 min of incubation of intact viral particles
with binase at the concentration of 1 × 105 U/ml. As
analyzed by RT-PCR at different cycle numbers (20, 25,
30 cycles), the protected full length viral RNA remained
unaffected by binase, suggesting that binase did not re-
duce the virus titer by affecting the cell free virus parti-
cles. The results described above argue against an
extra-cellular MOA of binase, but indicate that the
MOA is likely to be related to an effect within the host
cell (Fig. 2a).
Binase is accumulating in the cytosol of MDCK-II cells
To investigate whether binase exerts an intra-cellular
MOA, we first assessed the ability of binase to internalize
into MDCK-II cells. It was demonstrated before that
binase penetrated into A549 cells [23], nevertheless, we
wanted to assure that this would also be the case for
MDCK-II cells used in the present study. To determine
the possible intra-cellular accumulation of binase in
MDCK-II cells, fractions of binase-treated (1 × 105 U/ml)
cells were analyzed 8 h post-treatment (h p.t.) by Western
blotting. The results indicated that binase could also pene-
trate and accumulate in MDCK-II cells (Fig. 2b). Employ-
ing immunofluorescent staining and confocal microscopy,
we additionally showed that binase localizes mostly in the
cytosol of MDCK-II cells within 4 h p.t. (Fig. 2c). Based on
these results (Fig. 1 and Fig. 2), we speculate that the
intra-cellular, non-cytotoxic concentrations of binase
might exert an anti-viral effect on the viral RNA genome
within the infected MDCK-II cells.
Binase impairs IAV replication by attacking viral RNA
species within infected MDCK-II cells
Binase exerts an anti-viral effect during multicycle rep-
lication of IAV (Fig. 1b). Based on the finding that
binase can localize in the cytosol of MDCK-II at 4 h
p.t. (Fig. 2b, c), we investigated the intra-cellular effect
of binase on H1N1pdm09 during a single replication
cycle (12 h p.i.) and multiple replication cycles (24 h
p.i.). MDCK-II cells were treated with binase 4 h before
infection. Cells were then washed before adding the inocu-
lum that was subsequently replaced by binase-containing
media for up to 8 h after infection. The binase-containing
media was then replaced with fresh binase-free media and
virus titers were determined 12 (single-cycle) and 24 h
a b
Fig. 1 Cytotoxicity concentration 50% (CC50) and effective concentration 50% (EC50) of binase in MDCK-II cells. a The percentage of cell viability
was determined in MDCK-II cells, incubated with different compound concentrations for 24 h, via MTT assay. b The percentage of virus inhibition
was determined by comparing the reduction in viral titers, measured by foci assay, in H1N1pdm09-infected and binase-treated samples with
mock-infected controls. Bars represent the standard deviation of mean
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(multi-cycle) later. This way we intended to avoid any
extra-cellular effect of binase on the virus particles before
initial infection, as binase was absent during the infection
process. Washing the cells twice after removing the binase-
containing media before adding the fresh media without
binase, removed all remaining extra-cellular binase from
the cell monolayers. This had been verified by immuno-
fluorescent microscopy using an anti-binase primary anti-
body (data not shown). By analyzing H1N1pdm09 viral
titers, collected 12 h p.i., we found that binase could
significantly reduce viral propagation in MDCK-II cells by
22%. However, this virus reduction effect was potentiated
at 24 h p.i. to reach 87% (Fig. 3a).
To indicate that the observed binase intra-cellular
anti-viral effect against H1N1pdm is not strain specific,
we investigated the binase anti-viral activity against
H3N2-Vict under the same conditions (binase and
MDCK cells were incubated 4 h before infection and 8 h
p.i., MOI for H3N2 infection = 1, supernatants were ti-
trated 24 h p.i. for progeny virions load). Interestingly, a
significant reduction in the replication of H3N2-Vict
was observed (Fig. 3b).
We further determined the accumulation of vRNA,
cRNA and mRNA of the NP segment in single-cycle
replication (MOI = 3) by primer extension analysis using
total RNA isolated at 8 h p.i. from MDCK-II-infected
cells with H1N1pdm09 and either treated with 105 U/ml
binase or left untreated. Quantification (Fig. 3c) revealed
that, compared to H1N1pdm09-infected/binase untreated
MDCK-II cells, the H1N1pdm09-infected/binase treated
MDCK-II cells showed significant drop in the accumula-
tion of all viral RNA species in MDCK-II cells.
Therefore, we then checked of the NP expression
using western blotting. The western blot analysis of in-
fected and binase-treated MDCK-II cells (4 h before and
after infection) analyzed 4, 6 and 8 h p.i. revealed that
accumulation of the viral nucleoprotein (NP) was re-
duced during single-cycle replication by 36% and 24% at
6 and 8 h p.i., respectively (Fig. 3d). Taken together,
these data further support our understanding that binase
is intra-cellularly targeting the viral genome correspond-
ing with a reduction of viral proteins.
Binase does not affect expression of cellular housekeeping
genes
To assess the specificity of binase for viral RNA, the im-
pact of binase treatment (105 U/ml) on the expression of
cellular housekeeping genes in MDCK-II cells was inves-
tigated. RT-qPCR demonstrated that the transcript accu-
mulation of the MDCK-II housekeeping genes, ATPase
(ATP6V0E1) and Tubulin (TUBA4A), was not altered
upon binase treatment (Fig. 4a). This was further con-
firmed by comparable beta-actin protein expression levels
in binase-treated and untreated MDCK-II cells (Fig. 4b).
Therefore, we assume that binase specifically affects viral
genomic RNA and does not seem to alter cellular gene
expression and translation.
Binase reduces the gene expression of a H1N1pdm09
mini-genome system
The viral ribonucleoprotein (vRNP) complex of IAVs is
responsible for transcription and replication of the viral
genomic RNA and exists as a heterotrimeric polymerase




Fig. 2 Effect of binase incubation with virus particles and MDCK-II
cells. a To analyze the stability of genomic viral RNA (vRNA), virus
particles were either left untreated (lane 1) or treated with binase
(105 U/ml, lane 2) and incubated for 30 min at 37 °C. RT-PCR analysis
of the virus particle-protected vRNA, using specific segment primers
to amplify full-length PB2 segment for different number of cycles
(20, 25, 30, 35), showed that binase does not affect protected
H1N1pdm09 vRNA. b Internalization of binase (105 U/ml) into MDCK-II
cells was detected by Western blot analysis 8 h post incubation (lane
2). After washing the binase-treated cells twice, total cell lysate was
assayed. 100 ng of purified binase was used as a loading control (lane
1). M refers to protein size marker. c The internalization of binase
(105 U/ml) into MDCK-II cells was further analyzed by immunostaining
using rabbit polyclonal anti-binase and Alexa Fluor 488-labelled (green)
chicken monoclonal anti-rabbit antibodies 4 h post incubation. Cell
nuclei were stained with DAPI (blue). Control cells were not incubated
with binase
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subunits bound to the viral RNA, which is enwrapped
by the NP [34]. The plasmids encoding PB1, PB2, PA
and NP genes of H1N1pdm09 and a plasmid expressing
a vRNA-like Pol1 transcript encoding the open reading
frame of the chloramphenicol acetyltransferase (CAT)
reporter gene flanked by the 3′ and 5′ noncoding re-
gions of the NS RNA segment of influenza A/WSN/33
(H1N1) virus (pPol1-CAT-RT) were used to reconstitute
the viral RNP complex in vitro. Co-transfection of the
five plasmids into 293 T cells yielded CAT protein that
could be detected and quantified for its activity. The re-
sults obtained showed that the CAT activity of trans-
fected/binase-treated cells was significantly reduced by
12% and 24% at 1 × 104 U/ml and 1 × 105 U/ml, respect-
ively, in a concentration-dependent manner (Fig. 5). This
observation supports the idea that internalized binase
possibly affects IAV gene expression within infected
mammalian cells.
Discussion
Influenza-like illness is still a major health problem and
only few anti-viral approaches are approved. These few
licensed viral-protein-dependent antiviral therapies are
challenged by the continuous genomic evolution of influ-
enza A viruses (IAVs) to overcome the selective pressure
due to their overuse [35]. Consequently, new viral-
independent anti-viral strategies are urgently needed and
represent excellent alternative anti-influenza remedies.
Herein, we investigated the MOA of bacterial ribonuclease




Fig. 3 Intra-cellular effect of binase on viral replication and transcription. MDCK-II cells were pre-incubated with binase-containing media for 4 h,
washed twice with PBS++ and infected with either H1N1pdm09 or H3N2-Vict for 1 h (MOI = 1). Inoculum was then removed and cells were washed twice
with PBS++. DMEM/BA media, with and without binase, were added to the cell monolayers for 8 h p.i.. The cells were washed twice with PBS++ and fresh
infection medium without binase was added to the cells. The supernatants containing progeny virions were collected 12 and 24 h p.i. for H1N1pdm09
(a) or 24 h p.i. for H3N2-Vict (b) and titrated using foci assay. c Effect of binase on the activity of the viral polymerase activity of H1N1pdm09
as determined by primer extension analysis. MDCK-II cells were infected (MOI = 3) with H1N1pdm09. At 8 h p.i., vRNA, mRNA, cRNA, and 5S
rRNA (loading control) levels were determined. d Infected MDCK-II cells were treated with binase (105 U/ml, white bars) for the indicated time points
or left untreated (black bars) in triplicates. The effect of binase on viral NP production was analyzed by Western blotting using a NP-specific antibody
and calculated by setting the percentage of untreated cells at 100%. NP-specific signals were quantified and normalized to beta-actin expression
(loading control) and calculated relative to the values obtained from cells without binase treatment (arbitrarily set to 100%). Statistical analysis
was performed using the Student’s t-test and two-way ANOVA, followed by Bonferroni post hoc test (* = p < 0.05, ** = p < 0.01, *** = p < 0.001)
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detail to further evaluate the applicability of binase as a
potential anti-influenza agent.
The current influenza anti-viral drugs target the func-
tion of the variable surface glycoproteins, NA and M2.
This anti-influenza activity of NA-inhibitors and M2-
blockers can be easily subverted and resisted via
acquisition of distinct single or multiple amino acid (aa)
residues in the corresponding viral proteins [7]. In con-
trast, the genome of IAV (vRNAs) has highly conserved
regions, which can provide a constant site for targeting
by different ribonucleases. However, some natural ribo-
nucleases may be challenged with their high molecular
weight (Mwt), existence of natural RNAase inhibitors
and possible immunogenicity [36].
The bacterial ribonuclease, namely binase, is the guanyl-
specific RNAase from B. pumilus 7P with low Mwt
(12.2 kDa/109 aa residues). It is also preferred to other
natural ribonuclease being non-immunogenic and resist-
ant to mammalian RNase inhibitors in vitro and in vivo
[10, 17, 20]. Binase could be used intranasally or by intra-
venous injection and both administrations shown an anti-
viral effect of the enzyme in vivo [19, 20]. All of these fea-
tures emphasize that binase has the potential to be ef-
fective anti-influenza therapy.
In this study, the results obtained from the first set
experiments, including HAI and RT-PCR analysis of
binase-treated virions, could exclude a detectable effect
of binase on the ability of free virus particles to infect
MDCK-II cells. This finding restricts the MOA of
binase to an activity directly within the infected cell.
Yet, previous studies [13, 21, 22] observed an anti-viral
effect after pre-incubation of the virus with binase prior
to infection. This discrepancy might be explained by
the fact that the binase added to the virions before in-
fection was still present during infection. Therefore,
binase might have entered through the interaction of the
cationic binase protein with the negative charge of the cell
surface [13]. The receptors of the IAV hemagglutinin on
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a b
Fig. 4 Binase is not reducing the amount of host-cell transcripts and expressed proteins. a Real-time RT-PCR to analyze the expression levels of
the housekeeping genes mRNA transcripts ATPase (ATP6V0E1) and Tubulin (TUBA4A) in binase-treated (105 U/ml) and non-treated MDCK-II cells
at 12 h p.i. b Western blot analysis of cellular beta-actin protein expression levels in binase treated (105 U/ml) and non-treated MDCK-II cells.
Statistical significance was assessed using the Student’s t-test. *P < 0.1
Fig. 5 Impact of binase on the viral expression efficiency of the
H1N1pdm09 RNP complex. Effect of binase on the viral expression
activity of the H1N1pdm09 RNP complex was analyzed in 293 T cells
transfected with plasmids expressing the polymerase subunits (PB1,
PB2, and PA) and NP of H1N1pdm09 together with vRNA-like transcript
(pPol1-CAT-RT) encoding the CAT reporter gene, was analyzed for
CAT activity 48 h post transfection. The cells were treated with
104 and 105 U/ml of binase after transfection. In the control,
binase was absent. Statistical significance was investigated using
the Student’s t-test. ***P < 0.001
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the sialic acid [37, 38] allowing the binase to contact the
cell surface via electrostatic interaction and to be internal-
ized via endocytosis independently of the virus [39]. Since
the IAV enter the cells in a similar way, binase could
further utilize such endosomes for efficient uptake.
Interestingly, binase seems to have the ability to pene-
trate into cultured mammalian cells. In addition to the
MDCK-II cells used for this study, binase was previ-
ously reported to be detected in A549 cells [23].
Next we assessed the ability of binase to impair
H1N1pdm09 propagation at a non-toxic anti-viral con-
centration, while preventing direct interaction of virus
particles with binase prior to initial infection. Compared
to its anti-H1N1pdm09 activity at 24 h p.i., binase
showed a significant anti-viral effect at 12 h p.i., which
was not very strong probably due to the restricted up-
take and accumulation of the binase into the host cells
during the single replication cycle. This was overcome
after multicycle replication assayed after 24 h p.i.. This
significant anti-viral effect was also shown for a H3N2-
vict strain indicating that binase is efficiently working at
24 h p.i., regardless of the strain subtype. Based on these
aforementioned observations, we advanced to test the
idea of an intra-cellular MOA by investigating the effect
of binase on the accumulation of viral NP, viral RNAs,
mRNA of cellular housekeeping genes and on the ex-
pression activity of a mini-genome system. The quantifi-
cation of viral RNAs and of viral NP in binase-treated
cells, as well as of the amount of cellular mRNA encod-
ing housekeeping genes and the expression of a reporter
gene by the viral mini-genome are all showing an in-
hibitory effect of binase. In a similar way, it was re-
cently shown that the cellular double-stranded-RNA-
activated RNase L, a critical component of interferon-
regulated anti-viral host responses, exerts its anti-viral
activity during influenza virus infection by targeting
specific sites in viral RNAs [40]. Unlike the cellular
RNase L which has the tendency to target also the same
specific sites in host cell RNAs, no significant impact
on the expression of cellular housekeeping genes was
observed. This has further supported the hypothesis
that the IAV genome within the infected cell is the
main target of binase.
In light of these findings, our study verified the favor-
able and specific activity of binase in inhibiting the viral
replication of human IAVs in infected cells. Binase exerts
its anti-viral effects by specifically degrading viral RNA
species within the infected MDCK-II cells.
Conclusion
The present study provides novel findings on the anti-
viral properties and mode of action of binase. Here we
show that the bacterial ribonuclease binase inhibits
H1N1pdm09 propagation by degrading viral RNAs and
thereby impairing the viral gene expression within in-
fected MDCK-II cells, resulting in reduced intra-cellular
viral protein accumulation. Assuming that the mode of
action of binase is directed against the viral RNAs within
the infected cell it should be indiscriminative and effect-
ive, regardless of the IAV subtype. This supports the idea
of binase as a promising anti viral that might allow a
targeted anti-influenza approach.
Additional file
Additional file 1: Figure S1. The effect of binase on HA inhibition (HI).
Twofold serially diluted binase (105 U/ml) was incubated with 4HAU of
H1N1pdm09 and then supplemented with 1% chicken erythrocytes (RBCs) to
detect the binase/ligand interaction (binase + H1N1pdm+ RBCs). Meanwhile,
twofold serially diluted binase (105 U/ml) was incubated with 1% chicken
erythrocytes (RBCs) and then 4 HAU of H1N1pdm09 were added to explore
the binase/receptor interaction (binase + RBCs +H1N1pdm). HI assay was
conducted in triplicate for each serial dilution (1:10–1:1280).1xPBS, binase
(105 U/ml), and H1N1pdm09 (4 HAU) were used as controls. (PDF 432 kb)
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